Anavex Life Sciences Corp.
AVXL
$9.42
-$0.03-0.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.70M | 11.25M | 11.05M | 11.44M | 11.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.07M | 50.67M | 49.02M | 47.78M | 49.17M |
| Operating Income | -53.07M | -50.67M | -49.02M | -47.78M | -49.17M |
| Income Before Tax | -46.58M | -43.09M | -41.55M | -40.51M | -43.13M |
| Income Tax Expenses | -86.00K | -86.00K | -26.00K | 82.00K | 27.00K |
| Earnings from Continuing Operations | -46.49 | -43.00 | -41.53 | -40.59 | -43.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.49M | -43.00M | -41.53M | -40.59M | -43.16M |
| EBIT | -53.07M | -50.67M | -49.02M | -47.78M | -49.17M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.55 | -0.51 | -0.50 | -0.50 | -0.54 |
| Normalized Basic EPS | -0.35 | -0.32 | -0.31 | -0.31 | -0.33 |
| EPS Diluted | -0.55 | -0.51 | -0.50 | -0.50 | -0.54 |
| Normalized Diluted EPS | -0.35 | -0.32 | -0.31 | -0.31 | -0.33 |
| Average Basic Shares Outstanding | 336.60M | 333.87M | 331.05M | 327.39M | 323.23M |
| Average Diluted Shares Outstanding | 336.60M | 333.87M | 331.05M | 327.39M | 323.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |